MedTrace Logo

Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer

NCT03383835 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-05-23

No results posted yet for this study

Summary

This pilot study is an investigation of feasibility of moderate dose omega-3 fatty acid supplementation in pre-menopausal women at high risk for breast cancer who are considering future pregnancy. The goal of this pilot study is to determine feasibility of the study, document compliance with omega-3 fatty acid supplementation in this population and identify novel biomarkers modulated by moderate dose omega-3 fatty acids in this population.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3 Supplementation

DHA 600 milligrams (mg) per day for 6 months EPA 300mg per day for 6 months

Sponsors & Collaborators

  • University of Kansas Medical Center

    collaborator OTHER

  • American Cancer Society, Inc.

    collaborator OTHER

  • Lauren Nye

    lead OTHER

Principal Investigators

  • Lauren Nye, MD · The University of Kansas - Cancer Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-05
Primary Completion
2019-08-08
Completion
2024-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03383835 on ClinicalTrials.gov